Premium
Developmentally Modulated Cardiac Conduction Failure in Transgenic Mice with Fetal or Postnatal Overexpression of DNA Nonbinding Mutant Nkx2.5
Author(s) -
WAKIMOTO HIROKO,
KASAHARA HIDEKO,
MAGUIRE COLIN T.,
IZUMO SEIGO,
BERUL CHARLES I.
Publication year - 2002
Publication title -
journal of cardiovascular electrophysiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.193
H-Index - 138
eISSN - 1540-8167
pISSN - 1045-3873
DOI - 10.1046/j.1540-8167.2002.00682.x
Subject(s) - missense mutation , medicine , heart failure , mutant , genetically modified mouse , endocrinology , mutation , transgene , microbiology and biotechnology , biology , genetics , gene
Conduction Failure in Mutant Nkx2.5 Overexpression Mice.Introduction: Nkx2.5 is a conserved homeodomain (HD) containing transcription factor essential for early cardiac development. We generated a DNA nonbinding missense mutation, I183P in the HD, similar to the missense HD mutation found in patients. Transgenic mice expressing this mutation under β ‐MHC promoter [ β ‐MHC(I183P)] showed a postnatal lethal phenotype with heart failure. In contrast, mice expressing the mutation under α ‐MHC promoter [ α ‐MHC(I183P)] survive, with later onset heart failure. The aim of this study was to investigate the interrelationship between lethal cardiac failure and the electrophysiologic (EP) phenotypes using cardiac‐specific promoters with mutant gene expression at different stages of development and maturation. Methods and Results: In‐MHC(I183P) and wild‐type littermates, six‐lead ECG and in vivo endocardial EP studies were performed at 2.5, 3, 4, and 5 weeks of age. In α ‐MHC(I183P) and their wild‐type controls, ECGs were acquired at 3, 19, 31, and 64 weeks and in vivo EP studies assssed at 19 ± 4 weeks of age. β ‐MHC(I183P) mice display AV nodal, atrial, and ventricular EP dysfunction by 3 weeks of age. Bradycardia and PR prolongation were evident on telemetered ambulatory ECG of β ‐MHC(I183P) mice. In contrast, α ‐MHC(I183P) mice had no abnormalities on serial ECG through 31 weeks or EP findings at 19 weeks, except increased myocardial tissue refractoriness. However, by 64 weeks, PR intervals lengthened in α ‐MHC(I183P) mice. Conclusion: Both prenatal and postnatal overexpression of DNA nonbinding mutant Nkx2.5 are associated with AV conduction malfunction and heart failure; however, more profound progressive EP defects are seen when this mutation expresses during fetal and neonatal periods. These conduction abnormalities may contribute to the lethal heart failure and early mortality evident in DNA nonbinding mutant Nkx2.5 mice.